1.235USD+4.66%Mkt Cap: 66.13M USDP/E: —Last update: 2026-06-01
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezata…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap66.13M USD
Enterprise Value-28.99M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-77.74M USD
Revenue/Share—
Last Price1.235 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees54
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.10
PEG—
EV/EBITDA0.35
EV/Revenue—
P/S—
P/B0.61
EPS (TTM)-1.48
EPS (Forward)-1.09
52W Range
0.850037% of range1.880
52W High1.880 USD
52W Low0.8500 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-74.24%
ROA-66.70%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-73.58M USD
CapEx (TTM)29.00K USD
FCF Margin—
FCF Yield-71.17%
Net Debt-93.26M USD
Net Debt/EBITDA1.12
Balance Sheet
Debt/Equity0.01
Current Ratio11.14
Quick Ratio10.88
Book Value/Sh1.963 USD
Cash/Share1.754 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)4.333 USD
Target Range4.000 USD – 5.000 USD
# Analysts3
Ownership
Shares Out.53.33M
Float43.14M
Insiders3.35%
Institutions69.52%
Short Interest
Short Ratio7.3d
Short % Float5.98%
Short % Out.5.78%
Shares Short3.08M
Short (prev mo.)2.31M
Technical
SMA 501.360 (-9.2%)
SMA 2001.335 (-7.5%)
Beta—
S&P 52W Chg27.70%
Avg Vol (30d)356.33K
Avg Vol (10d)343.08K
Technical Indicators
RSI (14)33.6
MACD-0.0493
MACD Signal-0.0334
MACD Hist.-0.0159
BB Upper1.485 USD
BB Middle1.320 USD
BB Lower1.155 USD
BB Width25.02%
ATR (14)0.0659 USD
Vol Ratio (20d)0.92x